Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Active Pharmaceutical Ingredient Cancer Market

ID: MRFR/Pharma/49629-HCR
200 Pages
Rahul Gotadki
Last Updated: March 28, 2026

US Active Pharmaceutical Ingredient for Cancer Market Research Report: Size, Share, Trend Analysis By Types (Small Molecules, Biologics, Monoclonal Antibodies, Vaccines), By Applications (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer), By Manufacturing Process (Chemical Synthesis, Biotechnology, Extraction), and By Formulation (Tablets, Injectables, Oral Solutions, Topical) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Active Pharmaceutical Ingredient Cancer Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Billion)
      1. 4.1.1 Chemotherapy
      2. 4.1.2 Targeted Therapy
      3. 4.1.3 Immunotherapy
      4. 4.1.4 Hormonal Therapy
    2. 4.2 Healthcare, BY Drug Type (USD Billion)
      1. 4.2.1 Cytotoxic Drugs
      2. 4.2.2 Hormonal Agents
      3. 4.2.3 Biologics
      4. 4.2.4 Targeted Agents
    3. 4.3 Healthcare, BY Formulation Type (USD Billion)
      1. 4.3.1 Injectable
      2. 4.3.2 Oral
      3. 4.3.3 Topical
      4. 4.3.4 Intravenous
    4. 4.4 Healthcare, BY Route of Administration (USD Billion)
      1. 4.4.1 Intravenous
      2. 4.4.2 Oral
      3. 4.4.3 Subcutaneous
      4. 4.4.4 Intramuscular
    5. 4.5 Healthcare, BY End Use (USD Billion)
      1. 4.5.1 Hospitals
      2. 4.5.2 Oncology Clinics
      3. 4.5.3 Homecare Settings
      4. 4.5.4 Research Institutions
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Bristol-Myers Squibb (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Pfizer (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Merck & Co. (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Amgen (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Gilead Sciences (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Johnson & Johnson (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Eli Lilly and Company (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Novartis (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 AstraZeneca (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY APPLICATION
    3. 6.3 US MARKET ANALYSIS BY DRUG TYPE
    4. 6.4 US MARKET ANALYSIS BY FORMULATION TYPE
    5. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    6. 6.6 US MARKET ANALYSIS BY END USE
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    15. 6.15 HEALTHCARE, BY DRUG TYPE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY DRUG TYPE, 2024 TO 2035 (USD Billion)
    17. 6.17 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion)
    19. 6.19 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    21. 6.21 HEALTHCARE, BY END USE, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
      2. 7.2.2 BY DRUG TYPE, 2026-2035 (USD Billion)
      3. 7.2.3 BY FORMULATION TYPE, 2026-2035 (USD Billion)
      4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2026-2035 (USD Billion)
      5. 7.2.5 BY END USE, 2026-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormonal Therapy

Healthcare By Drug Type (USD Billion, 2026-2035)

  • Cytotoxic Drugs
  • Hormonal Agents
  • Biologics
  • Targeted Agents

Healthcare By Formulation Type (USD Billion, 2026-2035)

  • Injectable
  • Oral
  • Topical
  • Intravenous

Healthcare By Route of Administration (USD Billion, 2026-2035)

  • Intravenous
  • Oral
  • Subcutaneous
  • Intramuscular

Healthcare By End Use (USD Billion, 2026-2035)

  • Hospitals
  • Oncology Clinics
  • Homecare Settings
  • Research Institutions

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓